Allena pharmaceuticals, inc. (ALNA)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-43,505

-47,339

-45,591

-41,813

-39,187

-35,648

0

0

0

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

3,395

2,989

2,748

2,533

2,274

2,049

1,734

1,238

825

517

0

0

0

Depreciation expense

164

163

155

130

99

78

64

66

75

73

0

0

0

Non-cash interest expense

8

8

8

8

88

161

246

345

339

351

0

0

0

Amortization of operating lease assets

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash lease expense

0

-

-

-

0

-

-

-

-

-

-

-

-

Amortization of premium on investments

-

-

-

-

-

-

-

-

-

33

0

0

0

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

257

0

0

0

Changes in assets and liabilities:
Prepaid expenses and other current assets

1,000

202

-18

2,815

389

1,287

1,601

561

441

984

0

0

0

Other assets

-

-123

-191

-96

136

34

0

0

0

-

-

-

-

Accounts payable

-871

972

1,976

1,383

446

441

48

-337

824

199

0

0

0

Accrued expenses

0

-

-

-

0

-

-

-

-

-

-

-

-

Accrued expenses

-

-

-

-

-

-

-

0

436

-

0

0

0

Operating lease liabilities

-496

-531

0

0

0

-

-

-

-

-

-

-

-

Other liabilities

-

-

-

-

-

20

0

0

0

-

-

-

-

Net cash used in operating activities

-42,380

-43,632

-40,417

-39,556

-34,753

-31,839

0

0

0

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Purchases of property and equipment

-

122

284

304

371

318

157

116

37

57

0

0

0

Maturities of investments

-

-

-

-

-

-

-

-

-

24,721

0

0

0

Net cash (used in) provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash used in investing activities

-

-122

-284

-304

-371

-318

0

0

0

-

-

-

-

Proceeds from exercise of stock options

33

36

71

71

151

139

110

107

27

28

0

0

0

Repayment of loan payable

0

-

-

-

-

10,492

0

0

0

-

-

-

-

Payments of common stock offering costs

-

-

-

-

-

-

-

-

0

-

-

-

-

Other

-30

-29

0

0

0

-

-

-

-

-

-

-

-

Net cash (used in) provided by financing activities

11,114

12,118

9,561

9,530

497

-694

0

0

0

-

-

-

-

Net decrease in cash and cash equivalents

-31,304

-31,636

-31,140

-30,330

-34,627

-32,851

0

0

0

-

-

-

-

Supplemental disclosures:
Net cash (used in) provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

0

Right-of-use assets obtained in exchange of operating lease obligations

-

992

0

0

0

-

-

-

-

-

-

-

-

Accretion of convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

58

0

0

0